| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S80926-1mg促销 |
≥98% | ￥785.00 ￥706.00 |
6 | - | - | - | - |
|
S80926-5mg促销 |
≥98% | ￥1820.00 ￥1630.00 |
5 | - | - | - | - |
|
S80926-10mg促销 |
≥98% | ￥2360.00 ￥2130.00 |
8 | - | - | - | - |
|
S80926-25mg促销 |
≥98% | ￥4790.00 ￥4310.00 |
3 | - | - | - | - |
|
S80926-50mg促销 |
≥98% | ￥7210.00 ￥6480.00 |
1 | - | - | - | - |
|
S80926-100mg促销 |
≥98% | ￥10300.00 ￥9270.00 |
货期：3-5天 | - | - | - | - |
|
| 产品描述： | R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Cdk1/cyclin B:2 nM (Ki);CDK2/cyclinE:3 nM (Ki);CDK4/cyclin D:1 nM (Ki);cdk2/cyclin A:0.1 nM (IC50);CDK2/cyclinE:0.4 nM (IC50);Cdk1/cyclin B:0.2 nM (IC50);CDK3/Cyclin E:0.8 nM (IC50);CDK5/p35:0.1 nM (IC50);cdk6/cyclin D3:4 nM (IC50);CDK7/cyclin H:171 nM (IC50);GSK-3α:46 nM (IC50);GSK-3β:260 nM (IC50);Apoptosis;GSK-3;PKA;CDK | ||||||||||||||||||||
| 体内研究： | R547 has significant in vivo efficacy with daily oral and once weekly i.v. dosing. R547 inhibits phosphorylation of retinoblastoma protein in tumors | ||||||||||||||||||||
| 参考文献： | 1. Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer P, Yin X, Smith MA, Higgins BX, Chen Y, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N.Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4 2. Bayés M, Rabasseda X, Prous JR.Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jul-Aug;29(6):427-37. 3. Martin F, Thomson TM, Sewer A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, Peitsch MC.Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks.BMC Syst Biol. 2012 May 31;6:54. 4. DePinto, Wanda et al In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials Molecular Cancer Therapeutics (2006), 5(11), 2644-2658 5. Jones, Clifford D.; Andrews, David M. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors Bioorganic & Medicinal Chemistry Letters (2008), 18(24), 6486-6489 | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京